The global Tremfya market, valued at USD 3.92 billion in 2024, is projected to grow at a compound annual growth rate (CAGR) of 7.4% from 2025 through 2034. This sustained expansion reflects the drug’s established position in treating moderate-to-severe plaque psoriasis and its expanding label for psoriatic arthritis. Developed by Janssen Biotech, a subsidiary of Johnson & Johnson, Tremfya (guselkumab) is a human monoclonal antibody that selectively inhibits interleukin-23 (IL-23), offering a differentiated mechanism of action compared to other biologics targeting IL-17 or TNF-alpha pathways. As healthcare systems globally grapple with rising autoimmune disease prevalence, Tremfya continues to benefit from strong clinical trial outcomes, favorable reimbursement policies, and growing patient access.
North America remains the dominant region in the Tremfya market, accounting for the largest revenue share due to high psoriasis incidence rates, robust insurance coverage, and rapid adoption of biologic therapies. The U.S., in particular, benefits from a well-established dermatology care infrastructure, including specialty pharmacies and integrated health networks that facilitate biosimilar competition monitoring and patient adherence programs. Regulatory clarity provided by the U.S. Food and Drug Administration (FDA) has enabled Janssen to maintain a leadership position through strategic lifecycle management, including label expansions and long-term safety data submissions. Cross-border supply chains linking the U.S. with Canada and Mexico have ensured consistent availability of the drug, particularly under the United States-Mexico-Canada Agreement (USMCA), which streamlines pharmaceutical trade and manufacturing coordination.
Europe presents a mature yet highly competitive landscape, shaped by stringent pricing controls, centralized procurement systems, and increasing biosimilar penetration. Countries such as Germany, France, and the UK remain key contributors to market growth, supported by national treatment guidelines that favor IL-23 inhibitors over older TNF blockers due to their superior efficacy and longer dosing intervals. Regional manufacturing trends indicate a shift toward localized biologics production, with Janssen and other major players investing in contract manufacturing organizations (CMOs) across Ireland and Belgium to optimize supply chain resilience. Market penetration strategies in Europe increasingly emphasize value-based pricing models, risk-sharing agreements, and digital health integration to improve patient-reported outcome tracking and therapy compliance.
Read More @ https://www.polarismarketresearch.com/industry-analysis/tremfya-market
Asia Pacific, on the other hand, represents a high-growth potential region, driven by increasing awareness of chronic inflammatory diseases, rising healthcare expenditure, and evolving regulatory frameworks. Japan, South Korea, and Australia are leading adopters of advanced biologics, with Tremfya gaining traction due to its demonstrated superiority in head-to-head trials against ustekinumab and secukinumab. China, although still an emerging market, is witnessing accelerated uptake of imported biologics due to recent reforms in the National Reimbursement Drug List (NRDL) and expedited approval pathways introduced by the National Medical Products Administration (NMPA). Regional manufacturing trends are shifting toward partnerships between multinational pharma companies and local CMOs to reduce costs and ensure regulatory alignment with international standards.
The competitive landscape features several major players, including:
- Johnson & Johnson (Janssen Biotech)
- AbbVie Inc.
- Novartis AG
- Eli Lilly and Company
- Pfizer Inc.
- Sanofi S.A.
- Amgen Inc.
- Bristol-Myers Squibb Company
These firms are actively engaged in geographic diversification, pipeline innovation, and commercial partnerships aimed at strengthening their regional presence and optimizing supply chain efficiency in response to evolving market dynamics.
More Trending Latest Reports By Polaris Market Research:
Xerostomia Therapeutics Market
Ready-To-Drink Cocktails Market
Hemodynamic Monitoring Devices Market
